Glaucoma Pipeline

June 2010
Ocular Surgery News;6/25/2010, Vol. 28 Issue 12, p28
Academic Journal
The article presents update on pre-market approvals related to the treatment of glaucoma by the U.S. Food and Drug Administration (FDA), including the Healon D ophthalmic viscosurgical device from Abbott Medical Optics, Hi-Tech Pharmacal's abbreviated new drug application for dorzolamide hydrochloride-timolol maleate ophthalmic solution, and the orphan drug designation for Trabomycin from Mobius Therapeutics.


Related Articles

  • Glaucoma Drug Approval: Moving Beyond IOP. Chambers, Wiley A. // Ophthalmology Times;5/15/2012 Supplement, p19 

    The article focuses on the role of functional and structural endpoints in drug approval for glaucoma cure, as discussed by Wiley A. Chambers, from Center for Drug Evaluation and Research, U.S. Food & Drug Administration (FDA). Chambers said that a glaucoma treatment should be approved if it...

  • New glaucoma drug offers once-daily dosing.  // Drug Topics;6/21/2004, Vol. 148 Issue 12, p14 

    This article reports on the U.S. Food and Drug Administration approval for Istalol ophthalmic solution 0.5% for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. In clinical trials, the efficacy and safety profiles of once-daily Istalol...

  • Glaucoma Pipeline.  // Ocular Surgery News;4/10/2008, Vol. 26 Issue 7, p49 

    This section offers news briefs concerning glaucoma. Combigan has been approved by U.S. regulators as a treatment for glaucoma. Bioptigen has received a U.S. Food and Drug Administration (FDA) clearance for its Bioptigen OCT System. Mobius Therapeutics has received orphan drug designation for...

  • Glaucoma Pipeline.  // Ocular Surgery News;3/10/2008, Vol. 26 Issue 5, p23 

    This section offers news briefs on issues related to glaucoma treatment. The drug Combigan has been approved by U.S. regulators for the treatment of the disease. Marketing clearance has also been granted by the U.S. Food and Drug Administration (FDA) to Bioptigen for its Bioptigen OCT System for...

  • Generic Glaucoma Drugs Approved.  // Review of Ophthalmology;Dec2008 Part 1 of 2, Vol. 15 Issue 12, p9 

    The article reports on glaucoma drugs that have been approved by the U.S. Food & Drug Administration. It includes drugs Cosopt and Trusopt that are manufactured by Merck & Co. Inc., dorzolamide and timolol ophthalmic solution from Hi-Tech Pharmacal Co. Inc. and Prasco Laboratories Inc. which is...

  • FDA OKs POAG Marketing of Canaloplasty.  // Review of Ophthalmology;Sep2008 Part 1 of 2, Vol. 15 Issue 9, p11 

    The article reports that the U.S. Food and Drug Administration (FDA) has given iScience Interventional's microcatheters expanded indications for use in the treatment of primary open-angle glaucoma (POAG). It says that the minimally invasive surgical procedure called canaloplasty uses a...

  • FDA Briefs.  // Ophthalmology Times;10/15/2004, Vol. 29 Issue 20, p6 

    This reports on recent drug approvals granted by the U.S. Food and Drug Administration (FDA). The FDA has issued an approvable letter for its fixed combination of travoprost 0.004% and timolol 0.5% ophthalmic solution for the treatment of glaucoma, according to Alcon Laboratories, its...

  • In Brief.  // Ophthalmology Times;12/1/2008, Vol. 33 Issue 23, p3 

    The article offers news briefs related to ophthalmology in the U.S. The U.S. Food and Drug Administration (FDA) has granted pre-market approval to a pachymeter, auto-refractor, keratometer. Allergan Inc. has launched the over-the-counter artificial tear, Optive Sensitive Preservative-Free...

  • A Roundup of Recently Approved Ophthalmic Drugs (and Their Use in Practice). Rittenbach, Trennda; Pruitt, Joseph // Review of Optometry;Feb2014, Vol. 151 Issue 2, p22 

    The article discusses the expected potential of new ophthalmic topical medications approved by the U.S. Food and Drug Administration in clinical practice as of February 2014. Topics discussed include effectiveness of several glaucoma drops including Simbrinza and Zioptan, data on the potential...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics